X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The funding will be used in the development of Eisai's in-house developed agent E1224 (fosravuconazole) in Sudan for the treatment of mycetoma in partnership with the non-profit organization Drugs for Neglected Diseases initiative (DNDi).
Lead Product(s): Fosravuconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: E1224
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: $11.6 million Upfront Cash: Undisclosed
Deal Type: Funding May 25, 2023
Details:
The funding aims to bridge the gap between outcome of the E1224, fosravuconazole's randomized clinical trial (RCT), and access to fosravuconazole for treatment of eumycetoma in Sudan.
Lead Product(s): Fosravuconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: E1224
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GHIT
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Funding March 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
